Octocog alfa
Key facts
Invented name |
Advate
|
Active substance |
octocog alfa
|
Therapeutic area |
Haematology-Hemostaseology
|
Decision number |
P/65/2010
|
PIP number |
Octocog alfa
|
Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
Condition(s) / indication(s) |
Haemophilia A (congenital Factor VIII deficiency)
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Baxter AG
E-mail: juliana_brankova@baxter.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|